Erratum to: BioDrugs DOI 10.1007/s40259-013-0038-1 {#Sec1}
==================================================

A Published-Ahead-of-Print version of this article was made available online on 9 May 2013 at <http://link.springer.com/journal/40259/onlineFirst/page/1>.

Errors were subsequently identified in that version of the article, and the following corrections should be noted.

**Page 3, section 3.2.1, column 1, 1st paragraph, lines 9--13:**

The following phrase which reads:

"In the per-protocol population of the smaller study (*n* = 87), eribulin had an overall response rate of 11.5 %, whereas patients in the larger study had an overall response rate of 9.3 %; in both studies, all responses were considered partial \[27, 28\]."

should read:

"In the per-protocol population of the smaller study (*n* = 87), eribulin had an overall response rate of 11.5 %, whereas patients in the larger study [who met key inclusion criteria (eligible patients,]{.ul}*[n]{.ul}*[ = 269)]{.ul} had an overall response rate of 9.3 %; in both studies, all responses were considered partial \[27, 28\]."

**Page 5, section 3.2.2, column 1, 3rd paragraph, lines 4--7:**

The following phrase which reads:

"Patients were required to have previously received at most three chemotherapy regimens (at most two for advanced disease) with each regimen including an anthracycline or a taxane."

should read:

"Patients were required to have previously received [anthracycline and taxane therapy, and]{.ul} at most three chemotherapy regimens (at most two for advanced disease)."

**Page 5, section 3.2.2, column 1, 4th paragraph, line 1:**

The following phrase which reads:

"Like the EMBRACE study, eribulin increased the median overall survival of patients compared with capecitabine (15.9 vs 14.5 months; HR 0.88, 95 % CI 0.77, 1.00; *p* = 0.056; Table 4), although this difference was not statistically significant."

should read:

"[Eribulin]{.ul} increased the median overall survival of patients compared with capecitabine (15.9 vs 14.5 months; HR 0.88, 95 % CI 0.77, 1.00; *p* = 0.056; Table 4), although this difference was not statistically significant."

**Page 6, section 3.3, column 1, 4th paragraph, lines 3--9 and column 2, lines 10--14:**

The following phrase which reads:

"Adverse events were reported in 94.1 % of patients receiving eribulin and 90.5 % of patients receiving capecitabine; 17.5 and 21.1 % of patients reported serious adverse events \[31\]. More patients receiving eribulin had neutropenia (54 vs 16 %) and leukopenia (31 vs 10 %); however, the incidence of anaemia, thrombocytopenia and febrile neutropenia was similar between treatment groups \[31\]. Other common adverse events reported in patients receiving eribulin included alopecia (35 %), nausea (22 %), fatigue (17 %) and asthenia (15 %). Peripheral sensory neuropathy was observed in 13 % of patients (grade 3, 4 % of patients; no grade 4) \[31\]."

should read:

"[More patients receiving eribulin had neutropenia (54 vs 16 %) and leukopenia (31 vs 10 %); other common adverse events reported in patients receiving eribulin included alopecia (35 %) and nausea (22 %) \[31]{.ul}\]."

**Page 9, column 2, reference 31**

Reference should be replaced with:

"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Wanders J, et al. A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Res 2012; 72 (Suppl. 24): Abs S6-6."

**Page 10, column 2, references 50, 51 and 52**

References should be replaced with:

50\. "Vahdat L, Schwartzberg L, Glück S, Rege J, Liao J, Cox D, et al. Results of a phase 2, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer. Cancer Res 2012; 72 (Suppl. 24): Abs P1-12-02."

51\. "Vahdat L, Schwartzberg L, Wilks S, Rege J, Liao J, Cox D, et al. Eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer: results from a phase 2, multicenter, single-arm study. Cancer Res 2012; 72 (Suppl. 24): Abs P5-20-04."

52\. "Traina TA, Hudis C, Fornier M, Lake D, Lehman R, Berkowitz AP, et al. Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: preliminary results from a phase 2, single-arm feasibility study . Cancer Res 2012; 72 (Suppl. 24): Abs P1-13-11."

**Page 10, column 2**

The following reference should be inserted

"55. Pharmaceuticals and Medical Devices Agency, Japan. Halaven 1 mg Rinsyo Gaiyou, section 2.7.3-5, page 28 (Japanese only) \[online\]. Available from URL: <http://www.info.pmda.go.jp/shinyaku/P201100077/index.html> \[Accessed 2013 Jul 15\]."

**Page 4, Table**[**3**](#Tab1){ref-type="table"}**should be replaced with (bolded text is amended):**Table 3Phase II studies of eribulin in patients with metastatic breast cancer who have previously received an anthracycline and taxane*n*201 \[27\]211 \[28\]221 \[29\]**87 (per protocol population)269 (eligible population)**80 **(eligible population)**Prior chemotherapyAny prior regimen of chemotherapy with A and T (median 4)2--5 prior regimens of chemotherapy with A, T and CAP (median 4)≤3 prior regimens of chemotherapy including A and T (median 3)Dosing schedule1.4 mg/m^2^ IV inf\
d1 + 8 + 15 q4w\
1.4 mg/m^2^ IV inf d1 + 8\
q3w1.4 mg/m^2^ IV inf d1 + 8\
q3w1.4 mg/m^2^ IV inf d1 + 8\
q3wTumour response **(independent review)**PR (%)11.5 \[total\]9.321.310.2 \[q4w cohort\]14.3 \[q3w cohort\]SD (%)**42.5** \[total\]46.5**37.535.6** \[q4w cohort\]**57.1** \[q3w cohort\]ORR^a^ (%)11.5 \[total\]9.321.310.2 \[q4w cohort\]14.3 \[q3w cohort\]CBR^b^ (%)17.2 \[total\]17.127.511.9 \[q4w cohort\]28.6 \[q3w cohort\]Median duration of\
response (months)5.64.13.9Median PFS (months)2.62.63.7Median OS (months)9.010.411.1*A* anthracycline, *CAP* capecitabine, *CBR* clinical benefit rate, *d* day, *IV inf* intravenous infusion, *ORR* objective response rate, *OS* overall survival, *PFS* progression-free survival, *PR* partial response, *qXw* every *X* weeks, *SD* stable disease, *T* taxane^a^Objective response rate = complete response + partial response^b^Clinical benefit rate = complete response + partial response + stable disease ≥6 months

**Page 6, Table**[**5**](#Tab2){ref-type="table"}**should be replaced with (bolded text is amended):**Table 5Overall survival in the phase III studies of eribulin by human epidermal growth factor receptor 2 (HER2) and oestrogen receptor (ER) status305 (EMBRACE) \[30, **55**\]301 \[31, 32\]OS (months)HR (95 % CI)OS (months)HR (95 % CI)EribulinTPCEribulinCAPTotal**13.110.6**0.81 (0.66, 0.99)15.914.50.88 (0.77, 1.00)HER2+11.3^a^9.1^a^0.76 (0.47, 1.24)14.317.10.97 (0.69, 1.36)HER2−13.2^a^10.5^a^0.81 (0.64, 1.02)15.913.50.84 (0.72, 0.98)ER+13.8^a^11.4^a^0.81 (0.63, 1.04)18.216.80.90 (0.74, 1.09)ER−10.2^a^7.8^a^0.78 (0.54, 1.13)14.410.50.78 (0.64, 0.96)TN9.5^a^7.0^a^0.71 (0.46, 1.10)14.49.40.70 (0.55, 0.91)*CAP* capecitabine, *ER* oestrogen receptor, *HER2* human epidermal growth factor receptor 2, *TN* triple negative, *TPC* treatment of physician's choice^a^Values calculated from data available from the Pharmaceuticals and Medical Devices Agency, Japan. Halaven 1 mg Rinsyo Gaiyou \[55\]

The online version of the original article can be found under doi:10.1007/s40259-013-0038-1.
